CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic ...

Accelerated review was enabled by the Commissioner’s National Priority Voucher Pilot Program, targeting high unmet need and ...

If these results are validated by prospective trials, it could become a valuable tool for oncologists to assess results ...

Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...

Aggregating ‘negative’ immunotherapy trials can uncover reproducible immune perturbations that are missed in single studies, reframing lack of clinical benefit as potentially informative biologic ...

Adjuvant therapy with durvalumab (Imfinzi) and tremelimumab-actl (Imjudo) in patients with resected RCC was associated with early reductions in patient-reported quality of life (QoL), according to ...

Dr. Pooja Ghatalia presents findings from RETAIN-2, a single-arm phase 2 non-randomized trial evaluating a ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...

At the 2026 ASCO Genitourinary Cancers Symposium, Fred Saad, MD, presented encouraging phase 1 data evaluating the ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some of the most challenging diagnoses in modern medicine. From the introduction ...

Around the same time, LITESPARK-022 further positioned the drug in the second-line setting in combination strategies.